| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On November 11, 2026, Andrew Sinclair, Ph.D., a Class III member of the board of directors (the “Board”) of Adicet Bio, Inc. (the “Company”), notified the Company of his resignation from the Board, the Audit Committee of the Board (the “... |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Phase 1 data for prulacabtagene leucel (prula-cel, formerly ADI-001) demonstrated durable responses and a favorable safety profile in patients with systemic lupus erythematosus (SLE) with or without lupus nephritis (LN) |
| 28 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Forward-Looking Statements This presentation contains “forward-looking statements” of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words “anticip... |
| 08 Sep 2026 |
8-K: Regulation FD Disclosure
Forward-Looking Statements This presentation contains “forward-looking statements” of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words “anticip... |
| 01 Sep 2026 |
8-K: Regulation FD Disclosure
Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
Company to provide a comprehensive Phase 1 clinical update for prulacabtagene leucel (prula-cel, formerly ADI-001), featuring data from 22 patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE) with a minimum of 6 mont... |
| 18 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 17, 2026, Adicet Bio, Inc., a Delaware corporation (the “Company”), held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders considered and voted on the three proposal... |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition
Clinical update anticipated in mid-2026 for Phase 1 autoimmune program evaluating prulacabtagene leucel (prula-cel, formerly ADI-001) with at least 20 lupus nephritis (LN) and systemic lupus erythematosus (SLE) patients with a minimum of... |
| 28 Apr 2026 |
8-K: Unregistered Sales of Equity Securities
Adicet Bio, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [___________] or its registered assigns (the “Holder”) is... |
| 12 Mar 2026 |
8-K: Results of Operations and Financial Condition
Strong enrollment momentum in Phase 1 autoimmune program evaluating prulacabtagene leucel (prula-cel, formerly ADI-001); clinical update expected in 1H/2026 with an additional update in 2H/2026 |
| 07 Jan 2026 |
8-K: Regulation FD Disclosure; Other Events
Successfully completed meeting with FDA to align on and enable outpatient dosing of systemic lupus erythematosus (SLE) and lupus nephritis (LN) patients with prulacabtagene leucel (prula-cel, formerly ADI-001) in ongoing and future clini... |
| 29 Dec 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Other Events
REDWOOD CITY, Calif., December 26, 2025 – Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that... |
| 19 Dec 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On December 19, 2025, Adicet Bio, Inc., a Delaware corporation (the “Company”) held its 2025 Special Meeting of Stockholders (the “Special Meeting”). At the Special Meeting, the Company’s stockholders considered and voted on the two prop... |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition
Announced positive preliminary safety and efficacy data from Phase 1 clinical trial of ADI-001 in patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE); data highlighted rapid and sustained reductions in Systemic Lupu... |
| 07 Oct 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
As previously reported on April 7, 2025, Adicet Bio, Inc. (the Company or Adicet) received a notification letter (the Bid Price Letter) from The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that, for the last 30 consecutive bus... |
| 07 Oct 2025 |
8-K: Entry into a Material Definitive Agreement
Introductory. Adicet Bio, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 70,001,000 shares (the “Shares”) of its common st... |
| 07 Oct 2025 |
8-K: Other Events
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
Actively enrolling patients with lupus nephritis (LN), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) in Phase 1 clinical trial of ADI-001 in autoimmune diseases |
| 23 Jul 2025 |
8-K: Costs Associated with Exit or Disposal Activities; Other Events
On July 22, 2025, the Board of Directors of Adicet Bio, Inc. (the Company or Adicet) approved a reduction in its workforce by approximately 30% of the Company’s current employee base in connection with its strategic pipeline prioritizati... |
| 13 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 11, 2025, Adicet Bio, Inc., a Delaware corporation (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders considered and voted on the three proposals... |
Loading...